SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 787.37+3.4%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: The Ox who wrote (1885)4/1/2016 10:36:49 AM
From: Miljenko Zuanic  Read Replies (1) of 3559
 
Results are as good as expected, push toward other indications and higher WS price (hard in current environment when cancer drugs are "plugging" the system) would generate more positive environment.

J&J dropped (discontinue) anti-NGF Ab back to AMGN, PFE continue with planed and ongoing P3 (advantage with every 8 weeks dosing), so no idea how REGN stand with their candidate, Fasinumab.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News